Skip to content
Immunomet
MENUMENU
  • About
    • Overview
    • Management
    • Board of Directors
    • Oncology Clinical Advisory Board
    • Scientific Advisory Board
  • Development Programs & Science
    • Overview
    • Lixumistat (IM156) in Oncology
    • Lixumistat (IM156) in Fibrosis
    • Publications
  • Pipeline
  • Investors and Media
    • Featured Articles
  • Contact
Menu Close
MENUMENU
  • About
    • Overview
    • Management
    • Board of Directors
    • Oncology Clinical Advisory Board
    • Scientific Advisory Board
  • Development Programs & Science
    • Overview
    • Lixumistat (IM156) in Oncology
    • Lixumistat (IM156) in Fibrosis
    • Publications
  • Pipeline
  • Investors and Media
    • Featured Articles
  • Contact

Read more articles

Previous PostMedia-ImmunoMet Announces Initiation of Phase 1 Clinical Study of IM156
Next PostMedia-ImmunoMet Appoints Briggs W. Morrison

Recent Posts

  • ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
  • ImmunoMet Therapeutics Announces Closing of Series C Financing
  • Immunomet Therapeutic’s compound featured in the pre-publication from experts at Cambridge University entitled “Structural Basis of Mammalian Respiratory Complex I Inhibition by Medicinal Biguanides”
  • Immunomet Therapeutics Inc. announces publication of “First-in-human study of IM156, a novel biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors”.
  • ImmunoMet Therapeutics Closes $10M Series B-1 and Announces Plans to Conduct a Food Effect Study

Categories

  • Investors and Media

Contact Info

  • Headquarters: JLABS @TMC, 2450 Holcombe Blvd, Houston, TX 77021, USA
  • Email:dwelsch@immunomet.comOpens in your application
Copyright 2018 - ImmunoMet